Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial

The Lancet Neurology 2024 Feb 13:S1474-4422(24)00025-5. doi: 10.1016/S1474-4422(24)00025-5.  Cristina Tassorelli, Krisztián Nagy, Patricia Pozo-Rosich, Michel Lanteri-Minet, Sara Sacco, Tomáš Nežádal, Hua Guo, Rosa De Abreu Ferreira, Giovanna Forero, Joel M Trugman Abstract Background: Atogepant, an oral calcitonin gene-related peptide receptor antagonist, has been approved for the preventive treatment of

The Neuropsychiatric Safety Profile of Lasmiditan: A Comparative Disproportionality Analysis with Triptans

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2023 Sep;20(5):1305-1315.doi: 10.1007/s13311-023-01404-1. Epub 2023 Jul 12. Diane Merino, Alexandre O Gérard, Elise K Van Obberghen, Alexandre Destere, Michel Lanteri-Minet, Milou-Daniel Drici Abstract Migraine constitutes the world’s second-leading cause of disability. Triptans, as

Long-Term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study

Neurology 2021 Apr 28; doi: 10.1212/WNL.0000000000012029. Peter J Goadsby  , Uwe Reuter  , Michel Lanteri-Minet  , Gabriel Paiva da Silva Lima  , Peggy Hours-Zesiger  , Chrystel Fernandes  , Shihua Wen  , Nadia Tenenbaum  , Aditi Kataria  , Michel D Ferrari  , Jan Klatt  Abstract Objective: To report the efficacy and